Clinical trials: Partial Epilepsy
Focal Epilepsy
Improvement of the Accuracy of Spatial Representation of Invasive Exploratory Electrodes in Focal Epilepsy
Reconstruction software allows visualization of cortical structure in 3 dimensions, showing on a single picture the position of all the electrodes.
- Trial name
- ELEC3D (NCT02898935)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Epilepsy
Interest Balance Auto-immune Population in Patients With Focal Epilepsy of Unknown Cause, Not Structural, Not Genetics, Newly Diagnosed
The knowledge of encephalitis associated with antibodies targeting intracellular antigens, and neuronal surface antibody syndromes has expanded considerably in recent times.
- Trial name
- IBADEPIF (NCT02885207)
- Testing
- Focal epilepsy of unknown cause
- Where
- 4 sites in France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Strasbourg, France
Epilepsy, Partial-Onset Seizures
Study to Investigate Dosage, Efficacy, and Safety of Perampanel Given as Monotherapy in Patients With Epilepsy
The primary objective of this study is to assess the retention rate of perampanel when given as secondary monotherapy in routine clinical care.
- Conditions
- Epilepsy, Partial-Onset Seizures, Primary Generalized Tonic-Clonic Seizures
- Trial name
- NCT02736162
- Testing
- No treatment (intervention) was administered
- Volunteers
- 61 people
- Sponsor
- Eisai Inc.
Partial Seizures
Pregabalin In Partial Seizures (PREPS): An Open-Label, Multicenter Add On Therapy Trial
The purpose of this study is to assess the clinical improvement by partial seizures reduction, safety and tolerability of subjects having partial epilepsy related to the adjunction of pregabalin BID (75 to 300mg day titration…
- Trial name
- PREPS MEXICO (NCT00407797)
- Testing
- Pregabalin
- Where
- 8 sites in Mexico
- Volunteers
- 136 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Epilepsies, Partial
Vimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic Drug
The purpose of this study is to systematically and prospectively collect data from patients with partial-onset seizures in routine clinical practice setting receiving adjunctive Vimpat®.
- Trial name
- VITOBA (NCT01098162)
- Where
- 113 sites in Germany
- Volunteers
- 576 people
- Sponsor
- UCB Pharma GmbH
Focal Epilepsy
Lacosamide IV and EEG/EKG (LIVE) Study
The purpose of this study is to evaluate the effect of different intravenous doses (IV) of a new anti-epileptic drug (AED) called lacosamide on continuous EEG (electroencephalogram) rhythms (or brain rhythms) in subjects with…
- Trial name
- LIVE (NCT01724918)
- Testing
- Lacosamide
- Where
- 4 sites in Canada
- Volunteers
- 72 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Refractory Localization-related Epilepsy
A New Method for Delineation of Epileptic Brian Tissue During Epilepsy Surgery (The HFO Study)
Epilepsy occurs in 0.5-0.7% of the population, of which 25% are children. 30% Of patients with focal epilepsy do not respond well to medication and half of them are eligible for epilepsy surgery.
- Trial name
- NCT02207673
- Testing
- Tailoring of the resection based on biomarker in aEcoG during epilepsy surgery
- Where
- 2 sites in Netherlands
- Volunteers
- 78 people
- Sponsor
- UMC Utrecht
Partial Seizures
A Study of Levetiracetam as Monotherapy or Adjunctive Treatment of Partial Seizures in Pediatric Epileptic Subjects Ranging From 1 Month to Less Than 4 Years of Age
This is a study to confirm the efficacy of levetiracetam as adjunctive treatment or as monotherapy in pediatric epilepsy subjects aged 1 month to less than 4 years of age with partial seizures.
- Trial name
- PEACH (NCT03340064)
- Testing
- Levetiracetam
- Where
- 21 sites in Japan
- Volunteers
- 38 people
- Sponsor
- UCB Japan Co. Ltd.
Epilepsy, Temporal Lobe, Amygdalo-Hippocampal Epilepsy
EASINESS-TRIAL - Enhancing Safety in Epilepsy Surgery
To conduct a retrospective multicenter cohort study to define surgical benchmark values for best achievable outcomes following surgery for mesial temporal lobe epilepsy.
- Trial name
- NCT04952298
- Testing
- Mesial temporal lobe epilepsy surgery
- Where
- Germany
- Volunteers
- 1,500 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Focal Epilepsy
Breathing Rescue for SUDEP Prevention
The purpose of this study is to precisely delineate human brain networks that modulate respiration and identify specific brain areas and stimulation techniques that can be used to prevent seizure-induced breathing failure.
- Trial name
- BreatheS (NCT05981755)
- Testing
- Breathing tasks, Brain mapping with stimulation
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- The University of Texas Health Science Center, Houston
Focal Epilepsy, Generalized Seizure
Optimizing Therapy in Epilepsy Using Seizure Forecasts Via EEG and Wearables
Mayo Clinic is conducting a research study to test a new approach to managing seizures in people with epilepsy whose seizures have not been fully controlled with regular medications.
- Conditions
- Focal Epilepsy, Generalized Seizure, Drug Refractory Epilepsy
- Trial name
- FORESITE (NCT07012148)
- Testing
- UNEEG SubQ device, seizure forecasts, nasal diazepam, Preventative Medication (PM)
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Mayo Clinic
Partial Seizure Disorder, Epilepsy
Topiramate as Adjunctive Therapy in Infants 1-24 Months for the Control of Partial Onset Seizures
The purpose of this study is to evaluate the tolerability, safety and efficacy of topiramate in infants with refractory partial onset seizures (POS).
- Conditions
- Partial Seizure Disorder, Epilepsy, Seizures
- Trial name
- NCT00113815
- Testing
- topiramate
- Where
- 94 sites in United States, Argentina and 21 more
- Volunteers
- 118 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Epilepsy, Epilepsies, Partial
A Study of the Efficacy and Safety of Topiramate as add-on Therapy in the Treatment of Epilepsy Patients With Difficult to Treat, Partial-onset Seizures.
The purpose of this study is to evaluate the efficacy and safety of topiramate as add-on therapy in patients with difficult to control partial onset seizures who are taking one or two standard antiepileptic drugs.
- Conditions
- Epilepsy, Epilepsies, Partial, Seizures
- Trial name
- NCT00236691
- Testing
- topiramate
- Volunteers
- 188 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Epilepsy
Rufinamide Given as Adjunctive Therapy in Participants With Refractory Partial Seizures
To evaluate the effect of rufinamide on total partial seizure frequency in adolescent and adult participants (12 to 80 years, inclusive) with refractory partial onset seizures maintained on a maximum of 3 stable antiepileptic…
- Trial name
- NCT00334958
- Testing
- Rufinamide
- Where
- 77 sites in United States
- Volunteers
- 356 people
- Sponsor
- Eisai Inc.
Epilepsy
E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
The primary objective of this study is to determine the maximal tolerated dose (MTD) of E2007 given twice daily (bid) or once a day (qd) in patients with refractory partial-onset seizures (including secondarily generalized…
- Trial name
- NCT00144690
- Testing
- E2007 (perampanel)
- Where
- 5 sites in United States
- Sponsor
- Eisai Inc.
Drug Resistant Epilepsy, Temporal Lobe Epilepsy
The GABAergic Inhibitory System in Drug Resistant Epilepsy
This study aims to investigate the effect of lovastatin on neurotransmission and neuroinflammation in patients with temporal lobe onset drug resistant epilepsy.
- Trial name
- NCT06789497
- Testing
- Lovastatin 60 MG
- Where
- Portugal
- Volunteers
- 5 people
- Sponsor
- University of Coimbra
Epilepsy, Partial Seizures
A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years
Study A0081041 is a double blind, placebo controlled, randomized, parallel group, multicenter study to evaluate the safety and efficacy of two dose levels of pregabalin administered in equally divided daily doses, in either…
- Trial name
- PERIWINKLE (NCT01389596)
- Testing
- Pregabalin add-on therapy
- Where
- 86 sites in United States, Belgium and 16 more
- Volunteers
- 295 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Focal Epilepsy
A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy
The XEN1101 Phase 2 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of increasing doses of XEN1101 administered as adjunctive treatment in…
- Trial name
- X-TOLE (NCT03796962)
- Testing
- XEN1101
- Where
- 95 sites in United States, Canada and 7 more
- Volunteers
- 325 people
- Sponsor
- Xenon Pharmaceuticals Inc.
Epilepsy
A Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pharmacokinetics in Adolescents
This study is designed to investigate the short- and long-term effects of perampanel on cognition, growth, and development in adolescents.
- Trial name
- NCT01161524
- Testing
- Perampanel
- Where
- 37 sites in United States, Australia and 9 more
- Volunteers
- 133 people
- Sponsor
- Eisai Inc.
Focal Onset Seizure
Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy
Cenobamate (YKP3089) is a small molecule approved in the United States (US), Europe and several other countries around the world for the treatment of Partial-Onset (focal) seizures in adult subjects (≥18 years of age).
- Trial name
- NCT06453213
- Testing
- Cenobamate
- Where
- 19 sites in United States
- Volunteers
- 49 people
- Sponsor
- SK Life Science, Inc.